As a result, patients with prostate cancer that are treated with anti-AR therapy could be less susceptible to viral infection and the use of anti-AR compounds could be a therapeutic strategy and preventive option in these patients to avoid viral entry [110]. The gene discussed is AR; the disease is viral infectious disease.